Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Galecto Inc
GLTO | US
24.69
USD-0.72
-2.83%
GLTO | US
Loading StockChartView...
About Galecto Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
24.69
Open
25.85
High
25.89
Low
24.02
Galecto Inc. a clinical-stage biotechnology company develops molecules for the treatment of fibrosis cancer inflammation and other related diseases. The company's lead product candidate is GB2064 which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139 an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases such as idiopathic pulmonary fibrosis a life-threatening progressive fibrotic disease of the lung; GB2064 a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211 a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer as well as in Phase Ib/IIa for fibrosis. Galecto Inc. was founded in 2011 and is headquartered in Copenhagen Denmark.
View LessGLTO | US
Risk
43.0
Sharpe
1.63
Luna's Score
54/100
Recommendation
Hold
Luna says (GLTO | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
30.2%1 month
43.0%3 months
128.0%6 months
396.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.37
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
0.46
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-21.91M
MarketCap
32.37M
MarketCap(USD)
32.37M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-75.57
Short ratio
0.27
Short perc.
1.23
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
4.74
Range1M
5.84
Range3M
17.49
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.69
Price X volume
4.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.46 | 0.53 | Par |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.37 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 127.99 | 72.80 | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 32.37M | 3.66B | Emerging |
